Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157985 · ClinicalTrials.gov registry record · Phase 3
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
A Phase 3 study of Colorectal Cancer and Melanoma, sponsored by Dan Zandberg.
- Completed
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT04157985: Completed Phase 3 study of Colorectal Cancer and Melanoma, sponsored by Dan Zandberg.
NCT04157985 is a Phase 3 study of Colorectal Cancer and Melanoma that has completed, run by Dan Zandberg. The registered enrollment target is 161 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04157985, a Phase 3 study of Colorectal Cancer and Melanoma, has completed, sponsored by Dan Zandberg.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Primary Outcome
In patients who have already been treated with a PD-1 or PD-L1 inhibitor for one year, the difference in progression-free survival (time to next treatment, progression or death, whichever occurs first) between patients who stop treatment and patients who continue treatment.
Conditions Studied
Interventions
- DRUG Continue PD-1/PD-L1 Inhibitors treatment
- OTHER Discontinue PD-1/PD-L1-1 inhibitor
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2025-11-07 |
| Phase | Phase 3 |
What the finished NCT04157985 record still lists
NCT04157985 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (90% lower).
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Continue PD-1/PD-L1 Inhibitors treatment is the first listed.
NCT04157985 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04157985 about?
NCT04157985 is a clinical study titled "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors". Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment unti...
What is the current status of trial NCT04157985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2019-11-15. Estimated completion is 2025-11-07.
What conditions does trial NCT04157985 study?
This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Bladder Cancer, Gastric Cancer, Advanced Solid Tumors.
What interventions are being tested in trial NCT04157985?
The interventions under investigation include: Continue PD-1/PD-L1 Inhibitors treatment (DRUG), Discontinue PD-1/PD-L1-1 inhibitor (OTHER).
Who is sponsoring clinical trial NCT04157985?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04157985 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04157985's enrollment target sits among peer trials
161 165th of 381 higher than 216 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
The Northern-European Initiative on Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
COMPLETED · Phase 3
-
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 3
-
Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI